Effect of influenza vaccines against mismatched strains: A systematic review protocol

被引:8
|
作者
Tricco A.C. [1 ]
Chit A. [2 ,3 ]
Hallett D. [4 ]
Soobiah C. [1 ]
Meier G. [6 ]
Chen M. [1 ]
Tashkandi M. [5 ]
Bauch C. [7 ]
Loeb M. [8 ]
机构
[1] Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON
[2] GlaxoSmithKline, Mississauga, ON
[3] Faculty of Pharmacy, University of Toronto, Toronto, ON
[4] Institute of Medical Sciences, University of Toronto, Toronto, ON
[5] Applied Health Research Centre, St. Michael's Hospital, Toronto, ON
[6] North America Vaccines Division, GlaxoSmithKline, Philadelphia, PA
[7] Department of Mathematics and Statistics, University of Guelph, Guelph, ON
[8] McMaster University, Hamilton, ON
关键词
Antigenic variation; Cross protection; Influenza A virus; Influenza B virus; Protocol; Systematic review; Vaccines;
D O I
10.1186/2046-4053-1-35
中图分类号
学科分类号
摘要
Background: Influenza vaccines are most effective when the antigens in the vaccine match those of circulating influenza strains. The extent to which the vaccine is protective when circulating strains differ from vaccine antigens, or are mismatched, is uncertain. We propose to systematically review the cross-protection offered by influenza vaccines against circulating influenza A or B viruses that are not antigenically well-matched to vaccine strains.Methods/Design: This is a protocol for a systematic review and meta-analysis. Placebo-controlled randomized clinical trials (RCTs) reporting laboratory-confirmed influenza among healthy participants vaccinated with antigens of influenza strains that differed from those circulating will be included. The primary outcome is the incidence of laboratory-confirmed influenza (polymerase chain reaction (PCR) or viral culture). The secondary outcome is the incidence of laboratory-confirmed influenza through antibody assay (a less sensitive test than PCR or viral culture) alone or combined with PCR, and/ or viral culture. The review will be limited to RCTs written in English.We will search MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, previous influenza reviews, and the reference lists of included studies to identify potentially relevant RCTs. Two independent reviewers will conduct all levels of screening, data abstraction, and quality appraisal (using the Cochrane risk of bias tool).If appropriate, random effects meta-analysis of vaccine efficacy will be conducted in SAS (version 9.2) by calculating the relative risk. Vaccine efficacy will be calculated using the following formula: (1 - relative risk × 100). The results will be analyzed by type of vaccine (live attenuated, trivalent inactivated, or other). Subgroup analysis will include the effects of age (children, adults, older participants), and influenza A versus influenza B on the results. For influenza B we will also consider variable degrees of antigenic mismatch (lineage and drift mismatch).Discussion: Our results can be used by researchers and policy-makers to help predict the efficacy of influenza vaccines during mismatched influenza seasons. Furthermore, the review will be of interest to patients and clinicians to determine whether to get immunized or support immunization for a particular influenza season. © 2012 Tricco et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 50 条
  • [31] A systematic review of randomized clinical trials on quadrivalent influenza vaccines for adults
    Pellacchia, A.
    Mannocci, A.
    Millevolte, R.
    Chiavarini, M.
    de Waure, C.
    [J]. EUROPEAN JOURNAL OF PUBLIC HEALTH, 2022, 32
  • [32] Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review
    Jefferson, T
    Smith, S
    Demicheli, V
    Harnden, A
    Rivetti, A
    Di Pietrantonj, C
    [J]. LANCET, 2005, 365 (9461): : 773 - 780
  • [33] Effectiveness of seasonal influenza vaccines against influenza A (H1N1) infection in post-pandemic seasons: a systematic review
    Bozat-Emre, Songul
    Casaclang, Natalie
    Sinnock, Hasantha C.
    Ye, Xibiao
    Mahmud, Salaheddin M.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 178 - 179
  • [34] Universal influenza vaccines are futile when benchmarked against seasonal influenza vaccines
    Valkenburg, Sophie A.
    Poon, Leo L. M.
    [J]. LANCET INFECTIOUS DISEASES, 2022, 22 (06): : 750 - 751
  • [35] Porridge for influenza: Protocol for a systematic review and meta-analysis
    Sun, Haoxiang
    Mei, Manxue
    Xu, Jiayu
    Chen, Xiaofang
    Zhu, Wei
    Song, Jianping
    [J]. MEDICINE, 2022, 101 (46) : E31473
  • [36] Veterinary influenza vaccines against avian influenza in China
    Fan, Xiaoxu
    Hu, Yanxin
    Zhang, Guozhong
    Wang, Ming
    [J]. FUTURE VIROLOGY, 2015, 10 (05) : 585 - 595
  • [37] The effectiveness and safety of vaccines against human anthrax: a systematic review
    Demicheli, V
    Rivetti, D
    Deeks, JJ
    Jefferson, T
    Pratt, M
    [J]. VACCINE, 1998, 16 (9-10) : 880 - 884
  • [38] Effects of vaccines in patients with sickle cell disease: a systematic review protocol
    Wiyeh, Alison Beriliy
    Abdullahi, Leila Hussein
    Wonkam, Ambroise
    Wiysonge, Charles Shey
    Kaba, Mamadou
    [J]. BMJ OPEN, 2018, 8 (03):
  • [39] Vaccines against epidemic and pandemic influenza
    Hoelscher, Mary
    Gangappa, Shivaprakash
    Zhong, Weimin
    Jayashankar, Lakshmi
    Sambhara, Suryaprakash
    [J]. EXPERT OPINION ON DRUG DELIVERY, 2008, 5 (10) : 1139 - 1157
  • [40] Development of vaccines against pandemic influenza
    Wood, J.
    Robertson, J.
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S4 - S4